Position in EXEL
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$76,500
-$57,059 QoQ
Shares Held
1,406
-54.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Signature Equity Partners, LLC holds $405,689 across 27 Biotechnology names. EXEL ranks #2 (18.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
609 | $146,750 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
1,406 | $76,500 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
701 | $60,951 | |
| 4 | ACAD |
Acadia Pharmaceuticals Inc
|
1,762 | $44,578 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
51 | $25,333 | |
| 6 | RPRX |
Royalty Pharma plc
|
177 | $9,924 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
75 | $5,870 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
156 | $5,520 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $76,500 | 1,406 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $133,559 | 3,114 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $87,922 | 2,006 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||